49 reports of this reaction
2.9% of all NAFCILLIN SODIUM reports
#4 most reported adverse reaction
ACUTE KIDNEY INJURY is the #4 most commonly reported adverse reaction for NAFCILLIN SODIUM, manufactured by Athenex Pharmaceutical Division, LLC.. There are 49 FDA adverse event reports linking NAFCILLIN SODIUM to ACUTE KIDNEY INJURY. This represents approximately 2.9% of all 1,697 adverse event reports for this drug.
Patients taking NAFCILLIN SODIUM who experience acute kidney injury should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACUTE KIDNEY INJURY is a less commonly reported adverse event for NAFCILLIN SODIUM, but still significant enough to appear in the safety profile.
In addition to acute kidney injury, the following adverse reactions have been reported for NAFCILLIN SODIUM:
The following drugs have also been linked to acute kidney injury in FDA adverse event reports:
ACUTE KIDNEY INJURY has been reported as an adverse event in 49 FDA reports for NAFCILLIN SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACUTE KIDNEY INJURY accounts for approximately 2.9% of all adverse event reports for NAFCILLIN SODIUM, making it a notable side effect.
If you experience acute kidney injury while taking NAFCILLIN SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.